克拉斯
药代动力学
医学
肺癌
内科学
肿瘤科
药理学
癌症
结直肠癌
作者
Maximilian J. Hochmair,Karim Vermaelen,Giannis Mountzios,Enric Carcereny,Christophe Dooms,Se‐Hoon Lee,Éva Morócz,Terufumi Kato,Tudor‐Eliade Ciuleanu,Grace K. Dy,Bárbara Parente,Kenneth J. O’Byrne,Quincy Chu,Gilberto de Castro,Nicolas Girard,Wendy Snyder,Qui Tran,William Kormany,Brett E. Houk,Bhakti Mehta
标识
DOI：10.1016/j.ejca.2024.114204
摘要
Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
bc
归尘
冰魂
昏睡的蟠桃
顺心香菇
Auston_zhong
1111
我是站长才怪
斯寜
默默地读文献
back you up
糟糕的铁锤
nvatk16
月下独酌42
sutharsons
pluto
heavenhorse
落后导师
余味
皖公网安备34019202002308
